| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/21/2002 | WO2002014367A1 Chimeric human-type vascular endothelial cell growth factor |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014356A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | WO2002014355A2 Novel mitogen activated kinase |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | WO2002014319A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/21/2002 | WO2002014311A2 Urea compounds and methods of uses |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014308A1 Antithrombotic agents |
| 02/21/2002 | WO2002014291A1 PPARδ ACTIVATORS |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014283A1 Processes for preparing cilostazol |
| 02/21/2002 | WO2002014282A1 2-aminopyridine compounds and use thereof as drugs |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014273A1 Indoline derivatives as 5ht2c antagonists |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014270A1 New amidino derivatives and their use as thrombin inhibitors |
| 02/21/2002 | WO2002014269A2 2,4-substituted pyridine derivatives |
| 02/21/2002 | WO2002014267A1 Novel aminocyclohexane derivatives |
| 02/21/2002 | WO2002014265A1 Novel 3-substituted urea derivatives and medicinal use thereof |
| 02/21/2002 | WO2002014262A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | WO2002014251A1 Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
| 02/21/2002 | WO2002013982A1 Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
| 02/21/2002 | WO2002013872A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/21/2002 | WO2002013868A1 Dermatological formulation |
| 02/21/2002 | WO2002013852A1 Vascular relaxation agents |
| 02/21/2002 | WO2002013824A1 Cyclopentyl modulators of chemokine receptor activity |
| 02/21/2002 | WO2002013823A1 Micronized torsemide |
| 02/21/2002 | WO2002013821A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | WO2002013819A1 Seamless soft capsule preparations containing dihydrobenzofuran derivatives |
| 02/21/2002 | WO2002013816A1 Pharmaceutical composition |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013809A2 Compositions containing hypotriglyceridemically active stilbenoids |
| 02/21/2002 | WO2002013806A2 Compositions containing hypotriglyceridemically active stilbenoids |
| 02/21/2002 | WO2002013805A2 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 02/21/2002 | WO2002013804A2 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid |
| 02/21/2002 | WO2002013801A2 Method of treating the syndrome of coronary heart disease risk factors in humans |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013797A2 Therapeutic combination of a cetp inhibitor and atorvastatin |
| 02/21/2002 | WO2002013782A1 Oral delivery of peptide |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2002006247A8 Substituted amidoalkyl-uracils as parp inhibitors |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085668A8 Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001081328A3 Thiazolidinedione analogues and their use for the treatment of diabetes |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001057069A3 Targeting peptides |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001045717A3 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2001019158A3 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | WO2000054729A8 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 02/21/2002 | US20020022781 Products and methods for brachytherapy |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022642 As nitric oxide synthase (NOS) inhibitors, used in therapy and prophylaxis of central nervous system disorders, inflammatory disorders, septic shock and other disorders |
| 02/21/2002 | US20020022640 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022627 Inhibition of cyclooxygenase-2activity |
| 02/21/2002 | US20020022625 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 02/21/2002 | US20020022622 Administering effective amount of oxalzole, thiazole or imidazole derivatives to cure diseases associated with protein aging |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022617 Methods for increasing nitric oxide synthase activity |
| 02/21/2002 | US20020022615 Cyclic oxyguanidine protease inhibitors |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022604 4-oxo-4h-pyran derviatives; use as inhibitors of serine proteases; anticoagulants; treating thrombotic conditions including coronary artery and cerebrovascular diseases |
| 02/21/2002 | US20020022596 Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them |
| 02/21/2002 | US20020022595 Treating inflammation resulting from a response of the non-specific defense system in a mammal by administering an antiinflammatory agent and the uncontaminated Mac-1 alpha subunit |
| 02/21/2002 | US20020022587 Administering a compound which increases a transient potassium (K+ ) current in the excitable cells of a patient; losartan, saralasin for example |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | US20020022218 Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2 |
| 02/21/2002 | US20020022062 Using coffee bean extract |
| 02/21/2002 | US20020022046 Uses for medical devices having a lubricious, nitric oxide-releasing coating |
| 02/21/2002 | US20020022025 Anticoagulants |
| 02/21/2002 | US20020022022 Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors |
| 02/21/2002 | US20020020784 Flexible kite |
| 02/21/2002 | DE10039998A1 Neue substituierte Diareno-azepin-Derivate als Integrin Liganden New substituted Diareno-azepine derivatives as integrin ligands |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
| 02/21/2002 | CA2804958A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | CA2685447A1 Pharmaceutical composition |
| 02/21/2002 | CA2420032A1 Oral delivery of peptide |
| 02/21/2002 | CA2419985A1 Modulating multiple lineage kinase proteins |
| 02/21/2002 | CA2419790A1 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | CA2419406A1 Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels |
| 02/21/2002 | CA2419338A1 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| 02/21/2002 | CA2419245A1 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | CA2419181A1 Processes for preparing cilostazol |